Zim Laboratories Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
ZIMLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
ZIM Laboratories reported flat to slightly declining revenue for FY26 with standalone revenue from operations at Rs. 37,048 lakhs vs Rs. 37,564 lakhs in FY25. However, profitability deteriorated sharply with standalone PAT falling 49% to Rs. 597 lakhs from Rs. 1,174 lakhs, primarily due to higher raw material costs and other expenses. Consolidated PAT similarly declined 52% to Rs. 584 lakhs. Other income nearly doubled to Rs. 1,139 lakhs. The company generated positive operating cash flows of Rs. 4,766 lakhs. Deloitte Haskins & Sells LLP issued unmodified (clean) audit opinions for both standalone and consolidated results with no qualifications. The board also appointed Dhananjay V. Joshi & Associates as cost auditors for FY27.
The sharp profit decline despite stable revenues signals margin compression and cost pressures, which could concern investors. The clean audit opinion is reassuring, and strong cash generation indicates financial stability despite lower profitability.